Biotech

All Articles

Pfizer takes $230M attacked after axing fell short DMD gene treatment

.Pfizer's phase 3 Duchenne muscular dystrophy (DMD) genetics therapy breakdown has blown a $230 mill...

AC Immune observes 'site' prospective in Alzheimer's drug data

.After much more than 20 years of service neurodegenerative ailments, Swiss biotech a/c Immune syste...

GSK falls ph. 2 HPV injection over shortage of best-in-class prospective

.GSK has actually broken up a period 2 individual papillomavirus (HPV) vaccine from its own pipe aft...

OS Treatments refiles $6M IPO to cash HER2 medicine, preclinical ADCs

.OS Therapies will certainly list on the NYSE American supply exchange today by means of a $6.4 thou...

ALX's fizzling CD47 action cost sends supply spiraling down

.ALX Oncology's phase 2 stomach cancer action fee has weakened. After finding its own CD47 blocker e...

Ionis centers eye disease from targets of Roche-partnered possibility after data disappoint

.An Additional of Ionis Pharmaceuticals' key midphase readouts has actually disappointed desires, mo...

Biogen's CEO claimed no dangerous sell 2023. He's ready to be strong

.While Biogen's pharma peers are actually seeking for late-stage assets with little bit of danger, C...

Instil refills pipeline in $2B biobucks deal with ImmunOnco

.Instil Bio has been a biotech in search of a pipe after it ditched its lead possessions over the la...

Biogen leaves Denali Alzheimer's collab

.Biogen has actually returned rights to a very early Alzheimer's disease course to Denali Rehabs, le...

Takeda taps new head people oncology organization-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings...